202 filings
Page 4 of 11
8-K
IKT
Inhibikase Therapeutics, Inc.
13 Mar 23
Other Events
5:26pm
8-K
IKT
Inhibikase Therapeutics, Inc.
6 Mar 23
Departure of Directors or Certain Officers
4:55pm
4
IKT
Inhibikase Therapeutics, Inc.
3 Mar 23
Inhibikase Therapeutics / Milton H. Werner ownership change
5:00pm
4
IKT
Inhibikase Therapeutics, Inc.
3 Mar 23
Inhibikase Therapeutics / JOSEPH FRATTAROLI ownership change
5:00pm
SC 13D
IKT
Inhibikase Therapeutics, Inc.
24 Feb 23
Inhibikase Therapeutics / FiveT Investment Management ownership change
12:27pm
SC 13G/A
Milton H. Werner
16 Feb 23
Inhibikase Therapeutics / Werner Milton H. ownership change
12:00am
424B3
IKT
Inhibikase Therapeutics, Inc.
8 Feb 23
Prospectus supplement
9:13am
EFFECT
IKT
Inhibikase Therapeutics, Inc.
8 Feb 23
Notice of effectiveness
12:15am
D
IKT
Inhibikase Therapeutics, Inc.
7 Feb 23
$4.20 mm in options / securities to be acquired, sold $4.20 mm, 1 investor
4:48pm
UPLOAD
IKT
Inhibikase Therapeutics, Inc.
3 Feb 23
Letter from SEC
12:00am
CORRESP
IKT
Inhibikase Therapeutics, Inc.
3 Feb 23
Correspondence with SEC
12:00am
S-1
IKT
Inhibikase Therapeutics, Inc.
IPO registration
1 Feb 23
9:02pm
SC 13D
FiveT Investment Management Ltd
31 Jan 23
Inhibikase Therapeutics / FiveT Investment Management ownership change
11:59am
424B5
IKT
Inhibikase Therapeutics, Inc.
27 Jan 23
Prospectus supplement for primary offering
8:25am
8-K
IKT
Inhibikase Therapeutics, Inc.
26 Jan 23
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering
4:02pm
8-K
IKT
Inhibikase Therapeutics, Inc.
25 Jan 23
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson’s Disease
9:00am
8-K
IKT
Inhibikase Therapeutics, Inc.
24 Jan 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:27pm
8-K
IKT
Inhibikase Therapeutics, Inc.
17 Nov 22
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
4:30pm
10-Q
2022 Q3
IKT
Inhibikase Therapeutics, Inc.
Quarterly report
14 Nov 22
5:10pm
8-K
IKT
Inhibikase Therapeutics, Inc.
7 Nov 22
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs
4:01pm